ProThera

ProThera Biologics is a clinical-stage biotechnology company focused on the development of Inter-alpha Inhibitor Proteins (IAIP) for the treatment of severe inflammatory and infectious diseases. IAIPs are naturally occurring plasma proteins that act as critical modulators of the innate immune system and systemic inflammation. The company's lead therapeutic candidates are being evaluated for conditions including sepsis, COVID-19, and neonatal hypoxic-ischemic encephalopathy. By restoring depleted levels of these proteins, ProThera aims to prevent organ failure and improve survival rates in patients with acute inflammatory crises. The company has established a strategic partnership with Takeda to further develop its IAIP technology platform.